Quick Facts

• Therapeutic Domain: Treatment of hyperprolactinemic disorders.
• Primary Use: May help manage conditions associated with excessive prolactin levels.
• Benefit Profile: An available option for individuals requiring pharmacological management of this specific endocrine condition.

---

Gotabiotic Plus is a prescription medication utilized in the treatment of hyperprolactinemic disorders. This condition involves elevated levels of the hormone prolactin, which may be associated with various clinical manifestations.

This agent is indicated for individuals who require pharmacological support to address symptoms linked to excessive prolactin. Its primary role is to help manage these elevated hormone levels, which can contribute to the resolution of certain related clinical signs. It is considered an available option within the therapeutic approaches for this endocrine domain.

Use of Gotabiotic Plus should always be undertaken under the supervision of a qualified healthcare professional.

Gotabiotic Plus (Tobramycin/Dexamethasone ophthalmic) is a combination antibiotic and steroid medicine indicated only for steroid-responsive inflammatory ocular conditions where a risk of superficial bacterial infection exists.

Contraindications (Must Not Use)

Official regulatory information states that this medicine is contraindicated in patients with a known hypersensitivity to any component of the formulation. It must not be used by individuals with certain active ocular infections, as the steroid component (dexamethasone) can worsen these conditions. This includes:

• Viral diseases of the cornea and conjunctiva, such as epithelial Herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella.
• Mycobacterial infections of the eye.
• Fungal diseases of ocular structures.

Special Population Considerations

Population	Eligibility Status (Official)
Pediatric Patients (Under 2 years)	Safety and effectiveness have not been established (use not recommended).
Glaucoma Patients	Use requires special caution and routine monitoring of intraocular pressure, especially with long-term use.
Corneal Thinning	Use requires special caution due to increased risk of perforation.
Pregnancy	Use only if the potential benefit justifies the potential risk to the fetus (Category C).
Lactation	Caution should be exercised; it is not known if the drug passes into breast milk.

Note: Patients should not wear soft contact lenses during treatment. Prolonged use (10 days or more) is generally discouraged due to the risk of steroid-induced glaucoma and cataract formation.

The official regulatory profile for Gotabiotic Plus, an ophthalmic corticosteroid and anti-infective combination, is structured around documented risks of additive effects and pharmacokinetic interactions with systemic drugs.

Pharmacodynamic and Exposure Interactions

Official prescribing information notes that co-administration with Topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) carries an additive risk that may increase the potential for corneal healing problems or delay wound repair. Due to the low, but non-zero, systemic absorption of the Dexamethasone component, the label identifies a risk of increased systemic exposure when used concomitantly with potent inhibitors of the CYP3A4 enzyme, such as Ritonavir or Cobicistat.

This pharmacokinetic interaction may increase the risk of systemic corticosteroid-related side effects, including adrenal suppression. Furthermore, the use of this medicine alongside Systemic Aminoglycoside Antibiotics requires monitoring, as this combination has the potential for an additive systemic toxicity risk (e.g., neurotoxicity or ototoxicity).

Administration and Timing Constraints

For local administration, regulatory documents mandate a timing rule: when using this medicine concurrently with any other topical ophthalmic medicinal products (drops or ointments), an interval of at least 5 minutes must be allowed between successive applications. Ophthalmic ointments must be administered last to ensure proper drug retention.

Population-Specific Notes

The label includes a specific caution for patients with known or suspected Neuromuscular Disorders (such as Myasthenia Gravis), as the aminoglycoside component, Tobramycin, may aggravate muscle weakness due to its documented effect on neuromuscular function. No specific interactions are documented with food, alcohol, or herbal products.

The mechanism of action for Gotabiotic Plus is defined by two complementary, molecularly distinct actions that influence distinct biological processes.

Suppression via Glucocorticoid Receptor Modulation

This domain is governed by the Dexamethasone component, which acts as an agonist on intracellular Glucocorticoid Receptors (GR) to alter gene expression. This modulation suppresses the Arachidonic Acid Cascade by inhibiting the enzyme Phospholipase A2 (PLA2) , resulting in the limiting of local inflammatory mediator synthesis. The resulting physiological consequence is the modulation of the localized immune response, characterized by a decrease in fluid accumulation and leukocyte migration.

Bactericidal Action via 30S Ribosomal Inhibition

This domain is governed by the Tobramycin component, which directly and irreversibly inhibits bacterial protein synthesis by targeting the 30S ribosomal subunit. This causes the misreading of genetic code and the production of non-functional proteins, leading to a destructive bactericidal effect. This targeted pathway interference results in the cessation of susceptible bacterial proliferation. This mechanism represents the complementary anti-infective component of the drug's action.

How to Use Gotabiotic Plus: Official Administration Guidelines

Gotabiotic Plus (Dexamethasone and Tobramycin ophthalmic suspension) is administered exclusively via the topical ophthalmic route, meaning it is only for use in the eye. The product is an ophthalmic suspension and must be shaken well immediately prior to each instillation to ensure proper mixture of the active ingredients.

---

Administration Protocol

The standard adult dose is 1 or 2 drops per application, instilled into the conjunctival sac of the affected eye(s). This is typically scheduled every 4 to 6 hours. For acute inflammation, the dosing frequency may be increased to 1 or 2 drops every 2 hours during the initial 24 to 48 hours of therapy. The frequency of use should be decreased gradually as warranted by clinical improvement.

Procedural and Population Rules

In terms of procedural administration, if the medicine is used concurrently with other topical ophthalmic solutions, an interval of at least 5 minutes must be allowed between successive applications. Furthermore, contact lenses should not be worn while using the product. Dosing rules for specific populations confirm that the product is considered suitable for children 2 years of age and older at the adult dose, while dosage adjustments are generally not required for older adults.

Research Evidence / Overview of Studies for Gotabiotic Plus

Evidence for Use in Post-Surgical Ocular Care

Research has studied the use of the Gotabiotic Plus combination product in adults following certain eye surgeries, most commonly cataract extraction. Studies conducted for this indication include short-term Randomized Controlled Trials (RCTs), which are used to explore treatments under controlled conditions. These trials were primarily applied in studies examining short-term symptom patterns in patients following their procedure. Researchers monitored specific outcomes linked to inflammatory or irritative states, such as the grading of inflammation levels inside the front part of the eye, known as the anterior chamber cell and flare scores.

The findings describe patterns observed in the studies over the defined time intervals, typically lasting between one and three weeks. Research reports data related to the evolution of objective signs of inflammation during the study period. This evidence contributes to the broader evidence landscape regarding post-operative care and studies exploring inflammation and the risk of superficial bacterial infection.

Evidence for Use in Inflammatory Ocular Conditions

The combination was studied for use in research exploring specific eye conditions characterized by fluctuating or episodic manifestations where both inflammation and bacterial risk are factors. These studies included short-term, parallel-group comparative trials, which research examined how the product compares to other similar fixed-dose combination eye drops. The trials primarily involved adults presenting with certain ocular inflammatory conditions, such as blepharo-keratoconjunctivitis.

Duration of Research: Long-Term Studies and Follow-up

The clinical trials conducted for the main indications of Gotabiotic Plus generally involved follow-up durations that were limited, typically focused on the acute recovery period following surgery or the management of a flare-up. It is noted that long-term effects are not fully established through dedicated, multi-year clinical trials. Information on outcomes extending beyond the short-term study window is primarily derived from continuous monitoring and observation by regulatory agencies after the product has become available.

Evidence in Specific Patient Populations

The primary research exploring outcomes for Gotabiotic Plus results apply only to the populations studied, which were largely confined to adults (over 18 years of age). The research exploring the use of the combination for pediatric patients (children 2 years and older) in conditions like blepharo-keratoconjunctivitis remains an area where evidence is limited. Consequently, the data for certain groups remain insufficient to draw broad conclusions about the research structure for these groups.

Research Gaps and Areas of Uncertainty

The research highlights key areas where certainty remains low or where additional studies could provide further context. A recognized limitation is that the primary research data available focuses on the acute, short-term periods of observation. Furthermore, comparative evidence is lacking in some areas, and where comparative studies do exist, findings were mixed regarding the measured response patterns when stacked against every other available fixed-dose combination.

Common questions about Gotabiotic Plus (FAQ)

Q: Can I use Gotabiotic Plus to treat pink eye?

Official information indicates that Gotabiotic Plus is prescribed for steroid-responsive inflammatory ocular conditions where there is a risk of a superficial bacterial infection. The medicine is contraindicated (must not be used) in patients with viral diseases of the cornea and conjunctiva, such as epithelial Herpes simplex keratitis (dendritic keratitis). It is not formulated to treat viral infections.

---

Q: Can I take Gotabiotic Plus while drinking alcohol?

According to official product information, no specific interactions are documented between this topical ophthalmic medicine and alcohol. Regulatory documents also state that no interactions are documented with food or herbal products.

---

Q: What do I do if I miss a dose of the eye drops?

If a dose is missed, the standard recommendation is to apply it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the recommendation is to skip the missed dose and continue with the regular dosing schedule. Official patient information advises not to use double the dose to make up for a missed application.

Storage and Disposal of Gotabiotic Plus

Gotabiotic Plus (Tobramycin/Dexamethasone ophthalmic preparation) must be stored under specific, labeled conditions to maintain stability.

---

Storage Requirements

The medicine must be kept at room temperature, typically 20 C to 25 C (68 F to 77 F), and must be stored away from heat, moisture, and direct light. It is mandatory to keep the product from freezing and to ensure the container is kept tightly closed when not in use. The product must always be stored out of the reach of children.

---

Stability and Disposal

For the ophthalmic suspension, the medicine should not be used for longer than four weeks (28 days) after the first opening. Do not keep outdated medicine. Unused or expired medicine and its container must be disposed of in accordance with local, regional, and national regulations for pharmaceutical waste.